Charles River Laboratories International, Inc.’s Stock Price Drops to $206.54, Experiencing a 4.35% Decrease

Charles River Laboratories International, Inc. (CRL)

206.54 USD -9.40 (-4.35%) Volume: 0.98M

Charles River Laboratories International, Inc.’s stock price stands at 206.54 USD, experiencing a downturn by 4.35% in the current trading session, with a trading volume of 0.98M. The year-to-date performance highlights a decrease of 12.68%, indicating a challenging market for CRL.

Latest developments on Charles River Laboratories International, Inc.

Today, Charles River Laboratories stock price movements are influenced by several key events. The company announced the closure of its Skokie office, while Empower Advisory Group LLC sold shares of Charles River Laboratories. Additionally, the company is set to present at both UBS and Jefferies conferences, providing strategic updates and discussing its international revenue trends. Shareholders are also taking note of insider sales totaling US$5.2 million. Despite position adjustments by Amalgamated Bank and WCM Investment Management LLC, TD Cowen analyst predicts that Charles River Laboratories stock price is expected to rise.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Charles River Laboratories International, Inc. has a mixed long-term outlook. While the company scores well in areas such as Growth and Momentum, indicating positive potential for expansion and market performance, it falls short in areas like Dividend and Resilience. This suggests that while Charles River Laboratories may see growth and have strong momentum in the future, investors should be cautious about the company’s ability to provide consistent dividends and weather potential economic challenges.

Charles River Laboratories International, Inc. is a company that provides research tools and support services for drug discovery and development. They specialize in offering animal research models that are essential for the creation of new drugs, devices, and therapies. The company’s clientele includes pharmaceutical and biotechnology firms, as well as hospitals and academic institutions. With a mixed outlook according to the Smartkarma Smart Scores, investors may want to closely monitor Charles River Laboratories‘ performance in the coming years to assess its overall stability and growth potential.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma